Analytical Data
-
Gene name
GDF11
- Application
-
Alternative Names
GDF11；BMP11;Growth/differentiation factor 11
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
O95390
-
Expression Region
299-407aa
-
AA Sequence
NLGLDCDEHS SESRCCRYPL TVDFEAFGWD WIIAPKRYKA NYCSGQCEYM FMQKYPHTHL VQQANPRGSA GPCCTPTKMS PINMLYFNDK QQIIYGKIPG MVVDRCGCS
-
Molecular Weight
13 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
GDF11 (Growth Differentiation Factor 11) is a member of the TGF-β superfamily, known for its crucial role in various physiological processes, including development, tissue repair, and regeneration. Initially, GDF11 was identified for its involvement in muscle development and neural differentiation, but subsequent studies have highlighted its potential role in aging and rejuvenation. Research has shown that GDF11 levels decline with age, and this decline has been linked to various age-related diseases, including cardiovascular disorders and neurodegenerative conditions. The recombinant form of GDF11 has been developed for therapeutic applications, aiming to counteract the deficits associated with aging and promote tissue regeneration. Preclinical studies have indicated that administering GDF11 can enhance muscle regeneration and improve cognitive function in aging models, sparking interest in its potential as an anti-aging therapeutic agent. However, the precise mechanisms by which GDF11 exerts its effects, as well as the implications of its clinical application, remain under investigation. Ongoing research aims to elucidate the signaling pathways activated by GDF11, optimize recombinant protein production, and assess its safety and efficacy in human trials. The exploration of GDF11 as a therapeutic target reflects a growing interest in harnessing the regenerative capabilities of growth factors for improving healthspan and addressing the biological challenges posed by aging.
